ASX Health Stocks: Chimeric and Proteomics are making moves to get ready for clinical trials

Chimeric wants to accelerate its clinical trial readiness via a deal with WuXi
Recce advances to higher dosing in Phase I clinical trial
Proteomics engages experts to advance commercialisation

Chimeric signs deal with WuXi

Cell therapy specialist Chimeric Therapeutics (ASX:CHM) says it wants to get ready for multiple clinical trials.

The company entered into a partnership with WuXi ATU, a global contract testing and manufacturing organisation.

The deal will enable Chimeric to accelerate clinical manufacturing readiness for its CAR-T assets, and to support its multiple future clinical trials.

WuXi is based in Philadelphia and has over 1,300 employees across four sites worldwide.

It specialises in offering platforms to help develop, manufacture, and commercialise cell and gene therapies for customers worldwide.

Chimeric is currently testing two autologous CAR T-cell therapies for solid tumours.

The CHM 2101 (CDH17 CAR T) is in late preclinical development to treat multiple gastrointestinal cancers, including colorectal cancer, gastric cancer, and pancreatic cancer.

Meanwhile, the CHM 1101 (CLTX CAR-T) is currently being evaluated in a Phase 1 clinical trial to treat patients with recurrent or progressive glioblastoma.

Proteomics assembles a team of experts

Proteomics International (ASX:PIQ) says it has assembled a team of world leading clinicians specialising in nephrology and endocrinology to advise the company on its clinical and commercial initiatives.

The clinicians — from the US, Europe and Australia — are global experts in diabetes technology and care, and influential key opinion leaders in their respective fields.

PIQ has recently identified and validated a panel of protein biomarkers with the potential to treat oesophageal cancer.

Since October 2020, Proteomics and QIMR Berghofer have been collaborating on the development of a simple blood test for oesophageal adenocarcinoma, the most common form of oesophageal cancer.

Recce advances to higher dose

Following its Hong Kong patent grant announcement yesterday, Recce Pharma (ASX:RCE) has now advanced to a high dose level in its Phase I clinical trial of RECCE 327 (R327).

The trial has successfully completed the 1,000mg dosing of 36 human subjects, and will now advance into a higher dose of 2,000mg IV.

R327 is said to be one of the first new classes of antibiotics in over 30 years that allow its compounds to continuously kill bacteria and multi-drug resistant superbugs.